THE UNITED STATES PATENT AND TRADEMARK OFFICE

REVOCATION AND NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS

I, John S. Senaldi, President and CEO of Transform Pharmaceuticals, Iuc., the Assignee of the entire right, title, and interest in the U.S. Patent Application(s) and/or Patent(s) identified on the attached Schedule A, hereby revoke all previous powers of attorney or authorizations of agent given and do hereby appoint the attorneys or agents associated with the following Customer Number, with full power of substitution and revocation, to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith for the U.S. Patent Application(s) and/or Patent(s) listed in the attached Schedule A:

Customer Number: 76656

Please direct all correspondence in connection with said U.S. Patent Application(s) and/or Patent(s) to:

Customer Number: 76656

Respectfully submitted,

Date: 09-17-2010

John S. Senaldi President and CEO

Transform Pharmaceuticals, Inc.

THE UNITED STATES PATENT AND TRADEMARK OFFICE

STATEMENT UNDER 37 CFR 3.73(b)

Transform Pharmaceuticals, Inc., a Delaware Corporation, pursuant to 37 CFR 3.73(b), hereby states that it is the Assignee of the entire right, title, and interest in U.S. Patent Application(s) and/or Patent(s) on the attached Schedule A.

The entire right, title, and interest in the aforementioned Patent Application(s) and/or Patent(s) were conveyed to *Transform Pharmaceuticals, Inc.* via Assignment(s) recorded with the United States Patent and Trademark Office at the *Reel/Frame Numbers on the attached Schedule A.*

The undersigned, John S. Senaldi, President and CEO, has full authorization to act on behalf of Assignee, Transform Pharmaceuticals, Inc.

Respectfully submitted.

Date: 09-17-2010

John S. Senaldi President and CEO

Transform Pharmaceuticals, Inc.

				Schedule A		
Application Number	Filing Date	Patent Number	Issue Date	Title	Current Assignee	Reel/Frame
12/015,694	1/17/2008			NOVEL FLUNARIZINE SALT FORMS AND METHODS OF MAKING AND USING THE SAME	Transform Pharmaceuticals, Inc.	020695/0051
10/533,420	4/29/2005			METHOD FOR DETERMINING EFFECT OF PREFORMULATION FORMS ON THEIR DISSOLUTION RATES	Transform Pharmaceuticals, Inc.	015742/0041
12/143,220	6/20/2008			METHODS OF MANIPULATING SMALL AMOUNTS OF SOLIDS	Transform Pharmaceuticals, Inc.	015204/0358 & 015630/0810
10/599,804	10/20/2008			METHODS AND SYSTEMS FOR ANALYZING SOLIDS	Transform Pharmaceuticals, Inc.	021716/0848
11/413,353	4/28/2006	4/28/2006 7,763,112	7/27/2010	7/27/2010 METHODS AND SYSTEMS FOR CO- CRYSTAL SYNTHESIS	Transform Pharmaceuticals, Inc.	017709/0345
09/994,585	11/27/2001 7,108,970	7,108,970	9/19/2006	9/19/2006 RAPID IDENTIFICATION OF CONDITIONS, COMPOUNDS, OR COMPOSITIONS THAT INHIBIT, PREVENT, INDUCE, MODIFY, OR REVERSE TRANSITIONS OF PHYSICAL STATE	Transform Pharmaceuticals, Inc.	012578/0966
10/235,922	9/6/2002	9/6/2002 6,977,723	12/20/2005	1220/2005 APPARATUS AND METHOD FOR HIGH- Transform THROUGHPUT PREPARATION AND Pharmace SPECTROSCOPIC CLASSIFICATION AND CHARACTERIZATION OF COMPOSITIONS	Transform Pharmaceuticals, Inc.	013631/0700
11/051,517	1/31/2005 7,061,605	7,061,605	6/13/2006	6/13/2006 APPARATUS AND METHOD FOR HIGH- Transform THROUGHPUT PREPARATION AND SPECTROSCOPIC CLASSIFICATION AND CHARACTERIZATION OF COMPOSITIONS	Transform Pharmaceuticals, Inc.	015798/0826

		ratent			THELLING	
Number	Filing Date	Number	Issue Date	Title	Assignee	Reel/Frame
09/904,725	7/13/2001	7/13/2001 6,758,099	7/6/2004	7/6/2004 SYSTEM AND METHOD FOR	Transform	012009/0040
				OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS	Pharmaceuticals, Inc.	& 014006/0615
10/282,505	10/28/2002 6.852,526	6.852.526	2/8/2005	2/8/2005 TRANSDERMAL ASSAY WITH	Transform	013442/0214
				MAGNETIC CLAMP	Pharmaceuticals, Inc.	~
						015564/0762
10/371,372	2/20/2003	2/20/2003 7,172,859	2/6/2007	2/6/2007 SYSTEM AND METHOD FOR	Transform	012009/0040
				OPTIMIZING TISSUE BARRIER TRANSEED OF COMPOUNDS	Pharmaceuticals, Inc.	014006/0615
11/467.091	8/24/2006			COMPLITERIZED CONTROL OF HIGH-	Transform	018361/0356
				THROUGHPIIT TRANSDERMAI	Pharmaceuticals Inc	
				EXPERIMENTAL PROCESSING AND		
				DIGITAL ANALYSIS OF COMPARATIVE		
				SAMPLES		
10/694,639	10/27/2003 7,449,307	7,449,307	11/11/2008	11/11/2008 RAISED SURFACE ASSAY PLATE	Transform	014482/0118
					Pharmaceuticals, Inc.	
10/556,996	12/18/2005			RAISED SURFACE ASSAY PLATE	Transform	018647/0734
					Pharmaceuticals, Inc.	
10/439,943	5/16/2003	5/16/2003 6,908,760	6/21/2005	6/21/2005 RAISED SURFACE ASSAY PLATE	Transform	014158/0296
					Pharmaceuticals, Inc.	
11/573,237	8/4/2005			NOVEL FENOFIBRATE FORMULATIONS Transform AND RELATED METHODS OF	Transform Pharmaceuticals, Inc.	018025/0731
				TREATMENT		
11/197,880	8/5/2005	8/5/2005 7,642,287	1/5/2010	1/5/2010 NOVEL STATIN PHARMACEUTICAL	Transform	017319/0723
				METHODS OF TREATMENT	riiaiiiiaceuucais, iiic.	
11/462,142	8/3/2006			NOVEL FORMULATIONS COMPRISING	Transform	018048/0693
				FENOFIBRATE AND A STATIN, AND	Pharmaceuticals, Inc.	
				RELATED METHODS OF TREATMENT		
10/700,146	11/3/2003 7,449,342	7,449,342	11/11/2008	11/11/2008 METHODS OF MANIPULATING SMALL	Transform	015204/0358
				AMOUNTS OF SOLIDS	Pharmaceuticals, Inc.	& 015630/0810